Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome

Visceral Medicine

Volumn 32, Issue 5, 2016, Pages 329-334

  Grander, Christoph ^a   Grabherr, Felix ^a   Moschen, Alexander R ^a   Tilg, Herbert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Adiponectin; Cytokines; Inflammation; Insulin resistance; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALPHA TOCOPHEROL; ELAFIBRANOR; FARNESOID X RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIRAGLUTIDE; OBETICHOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO;

CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CHRONIC KIDNEY FAILURE; CYTOKINE PRODUCTION; DYSBIOSIS; ECHOGRAPHY; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN RESISTANCE; INSULIN SIGNALING; LIPOTOXICITY; LIVER FIBROSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW;

EID: 85030681747     PISSN: 22974725     EISSN: 2297475X     Source Type: Journal    
DOI: 10.1159/000448940     Document Type: Review

References (58)

1. Rinella ME: Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313: 2263-2273.
2. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE: From NAFLD to NASH to cirrhosis - new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013; 10: 627-636.
3. Michelotti GA, Machado MV, Diehl AM: NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10: 656-665.
4. Tilg H, Hotamisligil GS: Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006; 131: 934-945.
5. Gregor MF, Hotamisligil GS: Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415- 445.
6. Odegaard JI, Chawla A: Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013; 339: 172-177.
7. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F: Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389-397.e310.
8. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, Hultcrantz R: Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547-1554.
9. EASL-EASD-EASO: Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402.
10. EASL-EASD-EASO: Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016; 59: 1121-1140.
11. Bugianesi E: EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action? Diabetologia 2016; 59: 1145-1147.
12. Byrne CD, Targher G: EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate? Diabetologia 2016; 59: 1141-1144.
13. Toplak H, Stauber R, Sourij H: EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease: guidelines, clinical reality and health economic aspects. Diabetologia 2016; 59: 1148-1149.
14. Castera L: Noninvasive evaluation of nonalcoholic fatty liver disease. Sem Liver Dis 2015; 35: 291-303.
15. Tilg H, Moschen AR: Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846.
16. Samuel VT, Shulman GI: Mechanisms for insulin resistance: common threads and missing links. Cell 2012; 148: 852-871.
17. Glass CK, Olefsky JM: Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 2012; 15: 635-645.
18. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ, Ting JP: Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12: 408-415.
19. Moschen AR, Kaser S, Tilg H: Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab 2013; 24: 537-545.
20. Sun Z, Lazar MA: Dissociating fatty liver and diabetes. Trends Endocrinol Metab 2013; 24: 4-12.
21. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM: Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015; 62: 1148-1155.
22. Tilg H, Diehl AM: Cytokines in alcoholic and nonalcoholic steatohepatitis. New Engl J Med 2000; 343: 1467- 1476.
23. Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H, Kaser S, Kaser A, Tilg H: Antiinflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 2010; 59: 1259-1264.
24. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-190.
25. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M: IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-198.
26. Kiechl S, Wittmann J, Giaccari A, et al: Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med 2013; 19: 358-363.
27. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-26749.
28. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
29. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y: Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 1723-1732.
30. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8: 731-737.
31. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H: Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004; 323: 630-635.
32. Mandal P, Park PH, McMullen MR, Pratt BT, Nagy LE: The anti-inflammatory effects of adiponectin are mediated via a heme oxygenase-1-dependent pathway in rat Kupffer cells. Hepatology 2010; 51: 1420-1429.
33. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, Richelsen B: Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285:E527-533.
34. Turer AT, Scherer PE: Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012; 55: 2319-2326.
35. Wolf AM, Wolf D, Avila MA, Moschen AR, Berasain C, Enrich B, Rumpold H, Tilg H: Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. J Hepatol 2006; 44: 537-543.
36. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450- 455.
37. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
38. Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA: Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009; 32: 741-750.
39. Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS: Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008; 135: 1935- 1944, 1944.e1931.
40. Armstrong MJ, Adams LA, Canbay A, Syn WK: Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014; 59: 1174-1197.
41. Yki-Jarvinen H: Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2: 901-910.
42. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J, Yki- Jarvinen H: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028.
43. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V: A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013; 59: 550-556.
44. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR: Prevalence and associated factors of nonalcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29: 113-119.
45. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218.
46. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131.
47. Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R: Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharm Ther 2016; 43: 83-95.
48. Abrams GA, Kunde SS, Lazenby AJ, Clements RH: Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 2004; 40: 475-483.
49. Hyysalo J, Mannisto VT, Zhou Y, et al: A populationbased study on the prevalence of NASH using scores validated against liver histology. J Hepatol 2014; 60: 839-846.
50. Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM: Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56: 943-951.
51. Angulo P, Keach JC, Batts KP, Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
52. Byrne CD, Targher G: NAFLD: a multisystem disease. J Hepatol 2015; 62:S47-64.
53. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New Engl J Med 2010; 362: 1675-1685.
54. Ratziu V: Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol 2013; 10: 676-685.
55. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hubscher SG, Newsome PN: Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679-690.
56. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K: Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7: 678-693.
57. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, Mc- Cullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956-965.
58. Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A: Elafibranor, an agonist of the peroxisome proliferatoractivated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016; 150: 1147-1159.e1145.